Allergy Therapeutics (GB:AGY) has released an update.
Allergy Therapeutics has reported a financial recovery with an expected increase in H2 revenues to £21.6m, marking the first half-year growth since 2021, despite a full-year revenue decrease of 7%. Significant reductions in the company’s overheads have been achieved, and clinical advancements include successful trials for their Grass MATA MPL product and progress in their VLP Peanut vaccine trials. The company anticipates submitting a marketing authorization application for the Grass MATA MPL in Q4 2024, with ongoing shareholder support for funding requirements.
For further insights into GB:AGY stock, check out TipRanks’ Stock Analysis page.
